Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

被引：13
|
作者：
Barnet, Megan B. [1 ,2 ,3 ]
Cooper, Wendy A. [3 ,4 ,5 ]
Boyer, Michael J. [3 ,6 ]
Kao, Steven [3 ,6 ]
机构：
[1] Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia
[2] Univ New South Wales, Grad Res Sch, Sydney, NSW 2052, Australia
[3] Univ Sydney, Sydney Med Sch, Camperdown, NSW 2006, Australia
[4] Royal Prince Alfred Hosp, Camperdown, NSW 2006, Australia
[5] Western Sydney Univ, Sch Med, Penrith, NSW 2751, Australia
[6] Chris OBrien Lifehouse, Camperdown, NSW 2006, Australia
来源：
JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 06期
关键词：
non-small cell lung cancer; immunotherapy; checkpoint inhibitors; MAINTENANCE THERAPY; OPEN-LABEL; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB; ANTIBODY; NECROSIS; PLACEBO;
D O I：
10.3390/jcm7060151
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where best-case scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.
引用
收藏
页数：14
相关论文
共 50 条
  • [31] Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
    Rocco, Danilo
    Della Gravara, Luigi
    Ragone, Angela
    Sapio, Luigi
    Naviglio, Silvio
    Gridelli, Cesare
    CANCERS, 2023, 15 (19)
  • [32] Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy
    Chenlu Li
    Jingjing Pan
    Jing Luo
    Xupeng Chen
    BMC Pulmonary Medicine, 21
  • [33] Dendritic cell immunotherapy in non-small cell lung cancer
    Choi, Y.
    Chung, J.
    Shin, H.
    Cho, G.
    Sohn, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Prognostic Impact of Adjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer Following Neoadjuvant Immunotherapy
    Dong, Y.
    Xu, L.
    Si, H.
    Wu, J.
    Chen, T.
    Wen, J.
    Xie, H.
    She, Y.
    Zhao, D.
    Chen, C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S241 - S241
  • [35] PROGNOSTIC FACTORS IN NON-SMALL CELL LUNG CANCER
    O'Byrne, K.
    LUNG CANCER, 2009, 64 : S3 - S3
  • [36] Prognostic factors in non-small cell lung cancer
    Neffati, O.
    Fekih, L.
    Kammoun, H.
    Ayari, A.
    Mejri, I.
    Smadhi, H.
    Akrout, I.
    Abdelghaffar, H.
    Greb, D.
    Hassene, H.
    Megdiche, M. L.
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [37] Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer
    Bar, Jair
    Ofek, Efrat
    Barshack, Iris
    Gottfried, Teodor
    Zadok, Oranit
    Kamer, Iris
    Urban, Damien
    Perelman, Marina
    Onn, Amir
    LUNG CANCER, 2019, 138 : 109 - 115
  • [38] Autoantibodies: A promising prognostic tool for immunotherapy response in advanced non-small cell lung cancer
    Tarhoni, Imad
    Fhied, Cristina
    Pergande, Melissa
    Kollipara, Revathi
    Wakefield, Connor J.
    Gallo, Katherine
    Tangri, Apoorva
    Batus, Marta
    Fidler, Mary Jo
    Bonomi, Philip
    Borgia, Jeffrey A.
    CANCER RESEARCH, 2019, 79 (13)
  • [39] ACTIVE IMMUNOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER
    Neninger, Elia
    Camilo Rodriguez, Pedro
    Crombet, Tania
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S194 - S194
  • [40] Chemotherapy: A partnership with immunotherapy in non-small cell lung cancer
    Mendes, Ana Sofia
    Romao, Raquel
    Febra, Joana
    Azevedo, Sergio Xavier
    Fidalgo, Paula
    Araujo, Antonio
    THORACIC CANCER, 2023, 14 (05) : 437 - 441
12345